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Recent studies have demonstrated cyclooxygenase 2 (COX-2) overexpression in various human malignancies, especially in breast
cancer, where COX-2 turned out to be a predictor of poor survival. To evaluate the relation of COX-2 and Ep-CAM overexpression
and its prognostic significance, we performed a retrospective study on 212 breast cancer patients with a median follow-up time of
10.5 years. Overexpression of COX-2 in tumour tissue samples was assessed by immunohistochemistry. COX-2 overexpression was
found in 48.6% of the tumour samples and was predictive for poor disease-free and overall survival. Univariate analysis revealed a
strong correlation between COX-2 and Ep-CAM overexpression (P¼0.009). Concurrent COX-2 and Ep-CAM overexpression was
present in 21.7% of tumour specimens and had an additive negative impact on disease-free and overall survival. Determination of
both tumour markers should help in guiding new therapeutic strategies in patients with invasive breast cancer.
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Cyclooxygenase-2 (COX-2) is a prostaglandin synthase that
catalyses the synthesis of prostaglandin G2 (PGG2) and PGH2
from arachidonic acid. Recent studies have led to the recognition
of the importance of COX-2 in tumorigenesis of different tumour
types. It has been shown that COX-2 is involved in tumour
angiogenesis (Tsujii et al, 1998; Gately, 2000), in suppression of
apoptosis (Sheng et al, 1998) and in the promotion of invasiveness
(Tsujii et al, 1997). COX-2 overexpression was found in pancreatic
(Molina et al, 1999; Okami et al, 1999; Kokawa et al, 2001),
oesophageal (Zimmermann et al, 1999), prostate (Yoshimura et al,
2000), lung (Khuri et al, 2001), head and neck cancers (Chan et al,
1999) and in malignant gliomas (Shono et al, 2001). Tsujii et al
reported that COX-2 overexpression in intestinal epithelial cells
leads to downregulation of adhesion molecules (i.e. cadherins),
resulting in an enhanced tumorigenic potential (Tsujii and DuBois,
1995).
Enhanced COX-2 expression in breast cancer was first indicated
by reports of elevated prostaglandin levels in breast carcinomas
(Bennett et al, 1977), particularly in patients with metastatic
disease (Rolland et al, 1980). A key role of COX-2 for the initiation
and progression of breast cancer is suggested by the finding that
mere overexpression of COX-2 can be sufficient for inducing
mammary gland tumorigenesis in transgenic mice (Liu et al, 2001).
Notably, in human breast cancer cell lines, a positive correlation
was found between invasiveness, metastatic potential and pros-
taglandin production (Liu and Rose, 1996). Different groups have
described the prognostic significance of COX-2 overexpression in
breast cancer (Hwang et al, 1998; Ristimaki et al, 2002; Soslow et al,
2000).
We have recently described the prognostic significance of Ep-
CAM overexpression in patients with invasive breast cancer (Gastl
et al, 2000). Ep-CAM (also called 17-1A, ESA, EGP40, 323/A3) is a
40-kDa transmembrane glycoprotein expressed on most human
epithelial cells (Gottlinger et al, 1986). The Ep-CAM glycoprotein
functions as a homotypic intercellular adhesion molecule (Litvinov
et al, 1994) and has become a target for antibody-mediated
immunotherapy with the murine monoclonal antibody edrecolo-
mab (Riethmuller et al, 1998). So far, no data have been reported
on the correlation of COX-2 overexpression with Ep-CAM
overexpression in human breast cancer. We therefore examined
COX-2 and Ep-CAM overexpression in tumour specimens from
212 patients with invasive breast cancer, and analysed the
prognostic value of both tumour markers.
PATIENTS AND METHODS
Patient selection
A total number of 212 patients were included in this retrospective
analysis. This patient sample represents one-third of all cases with
localised invasive breast cancer who were operated at the
Department of Surgery, Innsbruck University Hospital, from
1980 to 1992. In fact, all cases for which paraffin-embedded tissue
samples were still retrievable from the local pathology repository
and for which clinical follow-up data were available, were included.
Only patients without evidence of distant metastasis at the time of
primary surgery and with well-documented axillary lymph node
status were eligible for this analysis. The median age of the patients
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ywas 54.2 years (range, 29–85 years). Patients younger than 50
years were considered premenopausal. Of the women, 112 (52.8%)
were node-positive and 100 (47.2%) node-negative. After primary
surgery the clinical status was documented by re-evaluating each
patient at least once annually at the Department of Surgery. The
evaluation procedure included physical examination, mammogra-
phy, abdominal ultrasound and chest radiography. The median
follow-up time was 10.5 years (range, 36–240 months). During this
observation period 96 patients relapsed. Of a total of 94 deaths, 84
were due to breast cancer, while 10 patients died without
documented disease recurrence.
Histopathology
All tumour samples were formalin-fixed, embedded in paraffin
wax and stored at the local pathology repository. Haematoxylin-
and eosin-stained slides were prepared from each tumour speci-
men using routine methods and then examined by light
microscopy. Histologic type and tumour grade were assessed by
one co-author (PO) in a blinded fashion using standard pathology
criteria.
Immunohistochemistry
COX-2 overexpression was determined by immunohistochemistry
using the murine monoclonal antibody COX-2 (Cayman, USA).
Briefly, 5-mm sections were cut from paraffin-embedded tissue
blocks, mounted on adhesive-coated glass slides, deparaffinised
and rehydrated. Endogenous peroxidase was inactivated by
immersing the slides in 0.3% H2O2 in absolute methanol for
20min at room temperature. Pretreatment consisted of a 15-min
incubation period in a water bath at 901C. After washing in Tris
buffer, slides were incubated for 2h with the primary antibody
(COX-2, Cayman, USA, dilution 1:100). Afterwards, a peroxidase-
conjugated goat anti-mouse antibody ready-to-use (EnVisiont,
DAKO, Vienna, Austria) was added for 30min. For immunostain-
ing, slides were then placed into the chromogen consisting of a
diaminobenzidine solution. Finally, slides were counterstained
with Mayer’s Hemalum solution. In addition, slides were
immunostained for Ep-CAM essentially as described previously
(Gastl et al, 2000; Spizzo et al, 2002).
Evaluation of slides
COX-2 overexpression was evaluated by two independent assessors
(GS and PO) using light microscopy. Reading of tissue slides was
blinded, and both assessors were unaware of clinical outcome.
COX-2 expression was defined as the presence of specific staining
in the cytoplasm of tumour cells. A final expression score was
calculated for each tissue sample by multiplying a staining
intensity score (0, negative; 1, weak; 2, moderate; 3, strong
staining) with a proportion score of positively stained cells
(1, 1–10%; 2, 11–50%; 3, 50–80%; 4, 80–100 %). Only samples
with a final expression score 44 were defined as ‘overexpressing’.
Ep-CAM overexpression was evaluated as previously reported
(Gastl et al, 2000; Spizzo et al, 2002).
Statistical methods
Statistical analysis was performed with the SPSS software program
for Windowst. The primary end points in this study were disease-
free and overall survival. Thus, survival curves were calculated
according to the method of Kaplan and Meier. P-values were
evaluated using the log-rank test for censored survival data.
Follow-up time was censored if the patient was lost to follow-up.
Patients who died without documented disease recurrence were
considered censored for disease-free survival but were included as
deaths for overall survival analysis. The relation between antigen
overexpression and other clinical or tumour parameters was
calculated with the w





Figure 1 (A) Example of an invasive ductal carcinoma with strong cytoplasmic COX-2 staining, classified as tumour with COX-2 overexpression. (B)
Tumour sample showing COX-2 overexpression in invasive lobular carcinoma surrounding normal epithelium lacking COX-2 expression (arrows) as
internal negative control. (C) Example of invasive ductal carcinoma presenting with strong membraneous Ep-CAM staining, classified as tumour with Ep-
CAM overexpression. (D) Invasive ductal carcinoma without Ep-CAM expression as negative control.
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yCOX-2 and Ep-CAM overexpression and established prognostic
markers, these variables were subjected to multivariate analysis
(Cox regression).
RESULTS
In normal mammary epithelium COX-2 showed absent to weak
staining (Figure 1B). COX-2 overexpression in tumour tissue
(Figure 1A) was found in 103 of 212 (48.6%) tumour specimens
and correlated with poor disease-free (P¼0.02, Figure 2A) and
overall survival (P¼0.04, Figure 2B). Remarkably, COX-2 over-
expression was significantly correlated with Ep-CAM overexpres-
sion (Po0.009; w
2 test), histologic tumour type (P¼0.011) and
menopausal status (p¼0.047) but failed to correlate with Her-2/
neu status or other tumour parameters (Table 1). In 46 (21.7%) of
the tumour specimens overexpression of both COX-2 and Ep-CAM
was found, while 79 (37.3%) showed neither COX-2 nor Ep-CAM
overexpression. Further, three distinct subgroups were identified
by the expression of COX-2 and Ep-CAM antigens (Figure 3A, B).
Patients with tumours overexpressing both antigens carried the
poorest prognosis. Median disease-free and median overall
survival time in this patient population were 55 months and 90
months, respectively. Patients overexpressing either COX-2 or Ep-
CAM had an intermediate prognosis with a median time to relapse
of 127 months and a median survival time of 147 months. Finally,
patients without overexpression of COX-2 and Ep-CAM in their
tumours carried the best prognosis. Median time to relapse and
median survival time for this patient group were not reached. By
subgroup analysis, overexpression of COX-2 in node-positive cases
predicted a dismal prognosis regarding disease-free and overall
survival, whereas in node-negative cases COX-2 overexpression
was of no prognostic value (data not shown). By multivariate
analysis, nodal status, Ep-CAM overexpression, tumour size and
histologic grade, but not COX-2 overexpression, proved to be
independent prognostic variables for overall survival. For disease-
free survival, nodal status, tumour size and Ep-CAM over-
expression, but not COX-2 overexpression, were independent
prognostic factors (Table 2).
DISCUSSION
Our study on 212 patients with invasive breast cancer confirms
previous reports that COX-2 overexpression is rather frequent in









































































Figure 2 COX-2 overexpression as prognostic marker in a patient
sample of 212 breast cancer patients. Patients with tumour tissue
presenting COX-2 overexpression (COX-2
+) had a significant shortened
disease-free intervall (A) and overall survival (B) as compared to patients
with tumours lacking COX-2 overexpression (COX-2
 ).




Characteristics no. no. % no. % P-value
a
Age at diagnosis
o50 93 55 59 38 41 0.047
X50 119 54 45 65 55
Histological type
Ductal 148 71 48 77 52 0.011
Lobular 45 22 49 23 51
Other types 19 16 84 3 16
Histologic grade
I 11 8 73 3 27 0.291
II 129 62 48 67 52
III 66 33 50 33 50
NE 6
Nodal status
pN0 100 51 51 49 49 0.909
pN1/2/3 112 58 52 54 48
Tumour size (cm)
o2 83 44 53 39 47 0.214
2–5 99 50 51 49 49




Neg: 0–9fmol 45 20 44 25 56 0.367




Neg: 0–9fmol 62 26 42 36 58 0.105




Pos 52 22 42 30 58 0.130
Neg 160 87 54 73 46
Ep-CAM
Pos 76 30 39 46 61 0.009
Neg 136 79 58 57 42
aw
2 test.
bUnknown cases are excluded from P-value calculation. NE=not evaluable.
COX-2 overexpression was significantly correlated with Ep-CAM overexpression,
histologic tumour type and menopausal status, but failed to correlate with other
tumour parameters.
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ythis patient population (Soslow et al, 2000) and predicts a dismal
prognosis for breast cancer patients (Ristimaki et al, 2002).
In experimental studies, COX-2 expression was related to local
tumour invasiveness and metastatic potential (Tsujii et al, 1997). It
has recently been demonstrated that COX-2 enhances angiogen-
esis, an effect that can be blocked by selective COX-2 inhibitors
(Masferrer et al, 2000). Thus, COX-2 overexpression may provide a
clinically useful biomarker for estimating tumour aggressiveness
and patients’ prognosis.
In our series, COX-2 overexpression was found to be absent in
normal mammary gland epithelium surrounding malignant tissue.
This observation is in keeping with recent data showing frequently
higher COX-2 expression in various epithelial neoplasia compared
with adjacent normal tissue (Soslow et al, 2000; Ristimaki et al,
2002).
Ep-CAM expression was found to correlate with cell prolifera-
tion and dedifferentiation in epithelial cells (de Boer et al, 1999).
To date, little is known about the molecular mechanisms
responsible for the regulation of the Ep-CAM gene. The highly
significant association of COX-2 and Ep-CAM overexpression
suggests a linkage between COX-2 and Ep-CAM signalling. Indeed,
Tsujii and DuBois (1995) demonstrated that COX-2 can disrupt
cell adhesion mediated by cadherins. Downregulation of cadherins
in turn can upregulate Ep-CAM expression. Moreover, cytokines
such as IFNa have been shown to upregulate both COX-2 and Ep-
CAM expression in epithelial tumour cells (Bostrom et al, 2001;
Flieger et al, 2001). Notably, no correlation was found between
Her-2/neu and COX-2 overexpression. This finding is somewhat
unexpected, since at least in colorectal cells, COX-2 can be
upregulated by Her-2/neu receptor signalling (Vadlamudi et al,
1999). Taken together, upon validation in prospective studies, the
combination of COX-2 and Ep-CAM expression may significantly
improve the estimation of breast cancer prognosis. Beside this,
COX-2 and Ep-CAM expression have come into focus as novel
targets for therapeutic interventions in colorectal cancer. It
remains to be seen whether COX-2 inhibitors and Ep-CAM
directed monoclonal antibodies turn out to be efficacious for the
treatment of other epithelial cancers such as breast carcinoma.
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Figure 3 Relationship between COX-2 and Ep-CAM overexpression
with disease-free survival (A) and overall survival (B). COX-2
+/Ep-CAM
+:
patients with tumours overexpressing both antigens, with a median disease-
free and overall survival of 55 and 90 months, respectively. COX-2
+/ /Ep-
CAM
+/ : patients with tumours overexpressing only one of the two
antigens, with a median disease-free and overall survival of 127 and 147
months, respectively. COX-2
 /Ep-CAM
 : patients with tumours without
overexpression of the antigens, where median disease-free and overall
survival were not reached.
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